ALLO Stock Forecast: Allogene Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.62
−6.76% on the day

The median 12-month analyst price target for Allogene Therapeutics, Inc. is $9. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 45 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$218.3M
Ticker Nerd rank
45/ 100
Median analyst target
$9.00
Analysts covering
12
Revenue$4.6M
Operating income−$46.9M
Net income−$42.7M
Free cash flow−$32.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−25.6%
1M
−53.0%
YTD
−54.4%
1Y
−49.6%
From 52W high
−79.6%
From 52W low
0.0%
$0.62
$3.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Allogene Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
45/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
74
Accruals
63
Growth
55
Volatility
45
Issuance
43
Momentum
42
Revisions
40
Value
22

Quality (74): The business earns solid, repeatable profits on what it owns.

Value (22): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALLO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALLO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26ALLOHigh $14.00Median $9.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11
Buy
1
Hold
0
Sell
$4.00
Low
$9.00
Median
$14.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
17 Aug 2026CitizensReiteratesMarket Outperform$6.00
16 Apr 2026HC Wainwright & Co.MaintainsBuy$12 → $11
16 Apr 2026JP MorganUpgradeNeutral—
15 Apr 2026JefferiesMaintainsBuy$6.00 → $10
14 Apr 2026Argus ResearchMaintainsMarket Perform$1.60 → $3.85
14 Apr 2026BairdMaintainsOutperform$7.00 → $9.00
14 Apr 2026BernsteinMaintainsMarket Perform$1.60 → $3.85
14 Apr 2026CitizensMaintainsMarket Outperform$5.00 → $8.00
14 Apr 2026HC Wainwright & Co.MaintainsBuy$8.00 → $12
13 Mar 2026Canaccord GenuityMaintainsBuy—
13 Mar 2026Piper SandlerMaintainsOverweight—
9 Jan 2026CitizensUpgradeMarket Outperform—
7 Jan 2026UBSInitiatesBuy—
10 Oct 2025JP MorganDowngradeUnderweight—
4 Aug 2025JMP SecuritiesReiteratesMarket Perform—
4 Aug 2025JP MorganDowngradeNeutral—
1 Aug 2025OppenheimerMaintainsOutperform—
15 May 2025CitigroupMaintainsBuy—
14 May 2025BairdMaintainsOutperform—
14 May 2025OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ALLO.

Market Radar

This page is one stock. Monday covers all of them.

ALLO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALLO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Allogene Therapeutics, Inc. returned −49.6% against +6.9% for the S&P 500, dividends included.

ALLO vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26ALLOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALLO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
46.9×

Cheaper than 5% of US stocks

Price / book
0.6×

Cheaper than 85% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−49.3%

Higher than 22% of US stocks

Return on assets
−25.4%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Allogene Therapeutics, Inc. has a market value of $218.3M and an enterprise value of $1.5M.

  • Revenue in the twelve months to 30 June 2026: $4.6M.

  • Net income over the same four quarters: −$165.5M, a −3566.7% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.67.

  • Free cash flow in the twelve months to 30 June 2026: −$102.6M.

  • Shares outstanding: 345.3M.

  • Allogene Therapeutics, Inc. employs 150 people — $31K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

ALLO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALLOAllogene Therapeutics, Inc.$218.3M45
IPSCCentury Therapeutics, Inc.$209.3M44
RCKTRocket Pharmaceuticals, Inc.$211.0M36
ARCTArcturus Therapeutics Holdings, Inc.$211.7M74
DTILPrecision BioSciences, Inc.$204.3M81
VNDAVanda Pharmaceuticals, Inc.$203.6M72
FTHFaeth Therapeutics, Inc.$203.1M26

Take a look at ALLO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Allogene Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ALLO

What is the ALLO stock price forecast for 2026-2027?

The median 12-month analyst price target for Allogene Therapeutics, Inc. is $9, with estimates ranging from $4 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALLO stock a buy right now?

Of the 12 analysts covering Allogene Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Allogene Therapeutics, Inc. 45 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALLO?

As at 21 Nov 2026, Allogene Therapeutics, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (74 of 100).

Will ALLO stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts is $9, and Ticker Nerd's factor model ranks Allogene Therapeutics, Inc. 45 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALLO stock forecast for 2030?

No analyst covering Allogene Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALLO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $14 over the next 12 months.

How has ALLO stock performed over the past year?

Allogene Therapeutics, Inc. returned -49.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Allogene Therapeutics, Inc. do?

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease. The company’s current work centers on investigational off-the-shelf cell therapy candidates designed to be manufactured from healthy donor cells and delivered more readily to patients than individualized treatments.

Company

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease. The company’s current work centers on investigational off-the-shelf cell therapy candidates designed to be manufactured from healthy donor cells and delivered more readily to patients than individualized treatments. Its pipeline includes programs targeting blood cancers, solid tumors, and autoimmune disorders, with emphasis on areas such as large B-cell lymphoma, renal cell carcinoma, and other oncology indications. Allogene Therapeutics also develops supporting technologies and manufacturing capabilities that are intended to improve the consistency, scalability, and accessibility of its cell therapy platform. Headquartered in South San Francisco, California, Allogene Therapeutics plays a specialized role in the immuno-oncology market as a developer of next-generation cell therapies for complex diseases.

CEO Dr. Zachary J. Roberts M.D., Ph.D. · 150 employees · United States · https://allogene.com